Fresenius Medical Care's top line has flattened to low single-digit growth, with revenue up roughly 1.1% year over year in 2026Q3, which suggests limited organic volume momentum.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue held near $4.6B to $5.1B per quarter while operating margin slid from 10.8% in 2025Q4 to 7.6% in 2026Q3 and net margin fell to 3.2%, suggesting cost pressure is outpacing top-line stability.
Wall Street analysts have a consensus twelve-month stock price forecast of $28.00 for Fresenius Medical Care, indicating potential upside.
Fresenius Medical Care is presented as a compelling deep-value, contrarian investment for long-term investors, especially after a significant share price decline.
The company has shown 38% growth in 2025 adjusted earnings per share, with a stable profit outlook for 2026.
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 3, 2026 | $0.64-1.7% vs $0.65 | $5.5B+0.0% vs $5.5B |
Q3 2026 Aug 3, 2026 | $0.66+7.1% vs $0.62 | $5.6B+2.2% vs $5.5B |
Q2 2026 May 5, 2026 | $0.53-10.2% vs $0.59 | $5.4B-0.1% vs $5.4B |
Q1 2026 Feb 24, 2026 | $0.83+28.3% vs $0.65 | $6.0B+5.3% vs $5.7B |
Fresenius Medical Care launches multiFiltratePRO kidney therapy system in the United States, expanding critical care options and growth opportunities.
Expands access to Fresenius Medical Care's globally established portfolio of advanced kidney replacement therapies in the U.S. FDA clearance of multiFiltratePRO and approval of dedicated solutions expand continuous kidney replacement therapy options for U.S. patients requiring treatment for acute kidney injury Integrated technology helps hospital intensive care teams deliver complex treatment simply and efficiently BAD HOMBURG, Germany, Oct. 21, 2026 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for people with kidney disease, today announced the U.S. launch of the multiFiltratePRO System for critically ill patients with acute kidney injury (AKI). multiFiltratePRO's integrated technology eliminates the need for separate citrate and calcium pumps, and automatically adjusts as treatment conditions change, making complex treatment easier for hospital intensive care teams to manage.
LAS VEGAS--(BUSINESS WIRE)--flyExclusive, Inc. (NYSE American: FLYX), one of the nation's largest private jet operators, today announced that Fly Alliance has agreed to replace its existing flight management system across its entire operation with Contrails FMS, flyExclusive's free, AI-powered aviation operating platform.The announcement, made at NBAA-BACE 2026, represents a significant milestone for Contrails FMS and introduces a new approach to aviation technology: providing operators with adv.
BAD HOMBURG, Germany, Oct. 19, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for people with kidney disease, presents new research and evidence-driven innovations aimed at improving patient outcomes during the American Society of Nephrology's (ASN) Kidney Week 2026, taking place October 21-25 in Denver, Colorado.
Benchmark FMS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Fresenius Medical Care AG & Co. KGaA (FMS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $23.40 | $12.57B | 13.37 | 1.51% | 4.22% | 5.9% | 3.32% | |
| $191.35 | $12.28B | 13.62 | 6.46% | 6.49% | 83.42% | — | |
| $30.42 | $275.03M | 12.00 | 33.46% | 24.12% | 12.06% | 2.01% | |
| $37.26 | $1.23B | -7.84 | -43.89% | -287.84% | -37.99% | — | |
| $25.79 | $13.32B | -18.55 | 5.72% | -6.23% | -11.67% | 2.63% | |
| $4.32 | $173.44M | -5.93 | — | — | — | — |
Fresenius Medical Care AG & Co. KGaA (FMS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when FMS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Fresenius Medical Care AG & Co. KGaA (FMS) stock FAQ — growth, dividends, profitability & financials explained
Fresenius Medical Care AG & Co. KGaA (FMS) reported $19.48B in revenue over the trailing twelve months. Revenue was $19.63B in fiscal year 2025. That is 557% more than the $2.99B of fiscal year 1998.
Fresenius Medical Care AG & Co. KGaA (FMS) revenue fell by 0.8% over the trailing twelve months, compared with the twelve months before.
Yes. Fresenius Medical Care AG & Co. KGaA (FMS) earned $822.8M in net income over the trailing twelve months (a 4.2% net margin).
Yes. Fresenius Medical Care AG & Co. KGaA (FMS) pays a dividend that yields 3.32% at the current price, a moderate yield.
Fresenius Medical Care AG & Co. KGaA (FMS) had a return on equity (ROE) of 5.9% over the trailing twelve months. That is below the market's typical 10-15%.
Fresenius Medical Care AG & Co. KGaA (FMS) generated $1.78B in free cash flow over the trailing twelve months.
